Phathom Pharmaceuticals reports Q3 2026 profit, strong revenue growth and reaffirms guidance

Phathom Pharmaceuticals announced third‑quarter 2026 net revenues of $84.7 million, a 71% year‑over‑year increase, and posted operating profit for the second straight quarter. The company generated $2.1 million of cash, posted an adjusted EPS of $0.04 beating estimates, and reaffirmed its full‑year revenue guidance of $310‑$325 million while noting a legal challenge to VOQUEZNA’s exclusivity.

The earnings call says the cash generation and operating profit signal a transition to self‑funding operations, which supports the stock’s valuation. Phathom also reaffirmed its FY2026 revenue guidance, giving investors a clear outlook despite the pending BDR Pharmaceuticals lawsuit challenging VOQUEZNA’s exclusivity period (the earnings call transcript notes).

Sources